DC101 monoclonal antibody

Known as: DC101 Mab, Mab DC101, DC101 
A monoclonal antibody that inhibits binding of vascular endothelial growth factor to its receptor, thereby inhibiting angiogenesis and tumor growth… (More)
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2005
Highly Cited
2005
Therapeutic monoclonal antibodies (mAbs) are currently being developed for the treatment of cancer and other diseases. Despite… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2004
Highly Cited
2004
Elevated interstitial fluid pressure, a hallmark of solid tumors, can compromise the delivery of therapeutics to tumors. Here we… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2004
Highly Cited
2004
A major obstacle compromising the successful application of many of the new targeted anticancer drugs, including angiogenesis… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2002
Highly Cited
2002
L ymphatic invasion is a commonly reported histopathological finding in the assessment of primary tumors. In some studies, it has… (More)
  • table 1
Is this relevant?
Highly Cited
2002
Highly Cited
2002
PURPOSE Anti-HER2 immunoliposomes combine the tumor-targeting of certain anti-HER2 monoclonal antibodies (MAbs) with the… (More)
Is this relevant?
Highly Cited
2001
Highly Cited
2001
Using an orthotopic intracerebral model, we investigated whether systemic treatment with DC101, a monoclonal antibody against… (More)
Is this relevant?
Highly Cited
2000
Highly Cited
2000
Various conventional chemotherapeutic drugs can block angiogenesis or even kill activated, dividing endothelial cells. Such… (More)
Is this relevant?
Highly Cited
2000
Highly Cited
2000
Vascular endothelial cell growth factor (VEGF) regulates angiogenesis and metastasis of bladder cancer (transitional cell… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
Highly Cited
1999
Highly Cited
1999
Tumor angiogenesis is mediated by tumor-secreted angiogenic growth factors that interact with their surface receptors expressed… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • table 1
Is this relevant?
Review
1998
Review
1998
Biological evidence suggests that interference with the function of the angiogenic growth factor receptor VEGFR2 (flk1/KDR) is a… (More)
Is this relevant?